You are here

Crohn’s disease

Takeda cuts 2 midstage GI assets including Crohn's hopeful in latest pipeline cleanup

Takeda cuts 2 midstage GI assets including Crohn's hopeful in latest pipeline cleanup

Fierce Biotech

Crohn’s disease

Flag link:

Prometheus Biosciences Catapults 176% On Promising Results In UC and Crohn's

Prometheus Biosciences Catapults 176% On Promising Results In UC and Crohn's

Investors Business Daily

Prometheus Biosciences

clinical trials

ulcerative colitis

Crohn’s disease

Flag link:

Pushing for top spot in Big Pharma, AbbVie lands a key approval for its blockbuster Skyrizi

Pushing for top spot in Big Pharma, AbbVie lands a key approval for its blockbuster Skyrizi

Endpoints

Crohn’s disease

Flag link:

Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s

Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s

Pharmaforum

clinical trials

Crohn’s disease

Flag link:

What AbbVie's Recent Drug News Means for Shareholders

What AbbVie's Recent Drug News Means for Shareholders

Motley Fool

Crohn’s disease

Flag link:

AbbVie's Rinvoq notches Crohn's disease win amid classwide JAK safety concerns

AbbVie's Rinvoq notches Crohn's disease win amid classwide JAK safety concerns

Fierce Pharma

Crohn’s disease

Flag link:

AbbVie seeks EMA approval for risankizumab (Skyrizi) to treat moderate to severe Crohn’s disease

AbbVie seeks EMA approval for risankizumab (Skyrizi) to treat moderate to severe Crohn’s disease

Pharmaceutical Business Review

Crohn’s disease

Flag link:

Theravance takes a gut punch as J&J-partnered JAK drug flops key test in ulcerative colitis

Theravance takes a gut punch as J&J-partnered JAK drug flops key test in ulcerative colitis

Endpoints

ulcerative colitis

Crohn’s disease

clinical trials

Flag link:

AbbVie's Skyrizi takes home a win in late-stage Crohn's study, adding some heft to its expansion plans

AbbVie's Skyrizi takes home a win in late-stage Crohn's study, adding some heft to its expansion plans

Endpoints

clinical trials

Crohn’s disease

Flag link:

Eli Lilly's mirikizumab improves fatigue in patients with Crohn's disease in Phase 2 trial

Eli Lilly's mirikizumab improves fatigue in patients with Crohn's disease in Phase 2 trial

Seeking Alpha

clinical trials

Crohn’s disease

Flag link:

After midstage flop, Janssen says thanks but no thanks to Provention Bio drug

After midstage flop, Janssen says thanks but no thanks to Provention Bio drug

Fierce Biotech

Crohn’s disease

Flag link:

Microbiome Report for the week ending 7-29-18

Microbiome Report for the week ending 7-29-18

CP Wire

Finch Therapeutics

Crohn’s disease

Alzheimer's disease

Flag link:

Microbiome Report for the week ending 7-29-18

Finch Therapeutics

Crohn’s disease

Alzheimer's disease

Flag link:

Takeda swoops in to buy stem cell partner TiGenix for $630M, putting it on the threshold of a likely approval

Takeda swoops in to buy stem cell partner TiGenix for $630M, putting it on the threshold of a likely approval

Endpoints

Crohn’s disease

Flag link:

How Big of a Deal Is Celgene's Flop?

How Big of a Deal Is Celgene's Flop?

Motley Fool

Crohn’s disease

Flag link:

Celgene just lost a crucial drug for its revenue stream after a clinical trial blowup

Celgene just lost a crucial drug for its revenue stream after a clinical trial blowup

Stat

Crohn’s disease

clinical trials

Flag link:

A drug used to treat Crohn’s disease could suppress HIV, monkey study suggests

A drug used to treat Crohn’s disease could suppress HIV, monkey study suggests

Stat

Crohn’s disease

Flag link:

AbbVie to Pay $595 Million for Boehringer Immunology Treatments

AbbVie to Pay $595 Million for Boehringer Immunology Treatments

Bloomberg

Boehringer Ingelheim

Crohn’s disease

Flag link: